论文部分内容阅读
目的观察伴有高血压病的代谢综合征(metabolic syndrome,MS)患者血浆血管性假血友病因子(vonWille-brandfactor,vWF)水平及应用缬沙坦后vWF的变化。方法测定22例伴有高血压病的MS患者服用缬沙坦80mg/d4周前后及29例健康体检者血浆vWF含量。结果伴高血压病的MS患者血浆vWF显著高于健康对照者[(176±24)%vs(130±26)%,P<0.01];vWF含量与收缩压(SBP)[r=0.60,P<0.01]、舒张压(DBP)[r=0.57,P<0.01]、平均动脉压(MAP)[r=0.61,P<0·01]、体质量指数(BMI)[r=0·53,P<0.01]、三酰甘油(TG)[r=0.36,P<0.05]、总胆固醇(TC)[r=0.49,P<0.01]、空腹血糖(FBG)[r=0.45,P<0.01]呈正相关;缬沙坦治疗4周后,伴高血压病的MS患者血浆vWF水平较治疗前显著降低[(160±15)%vs(176±24)%,P<0.01]。结论伴高血压病的MS患者血浆vWF水平较健康人明显增高;予缬沙坦治疗后,在有效降低血压的同时,可短期内降低vWF水平,改善血管内皮功能。
Objective To investigate the plasma level of von Wille-brand factor (vWF) and the change of vWF after valsartan treatment in hypertensive patients with metabolic syndrome (MS). Methods The plasma levels of vWF in 22 patients with essential hypertension were measured before and after valsartan 80 mg / d for 4 weeks and 29 healthy subjects. Results The plasma vWF level in MS patients with hypertension was significantly higher than that in healthy controls [(176 ± 24)% vs (130 ± 26)%, P <0.01]. The vWF content and systolic blood pressure (SBP) (P <0.01), DBP (r = 0.57, P <0.01), MAP (r = 0.61, P <0.01), BMI (r = 0.53, (R = 0.36, P <0.01), total cholesterol (r = 0.49, P <0.01), fasting blood glucose (P <0.01). The plasma levels of vWF in MS patients with hypertension were significantly lower than those before treatment [(160 ± 15)% vs (176 ± 24)%, P <0.01] after 4 weeks of valsartan treatment. Conclusions Plasma vWF levels in MS patients with hypertension are significantly higher than those in healthy people. After valsartan treatment, vWF levels can be reduced in a short period of time while blood pressure is effectively reduced, improving vascular endothelial function.